Use of Selincro and Impact on Usual Practice

Launched by UNIVERSITY OF BORDEAUX · Jul 3, 2015

Keywords

ClinConnect Summary

Selincro® (nalmefene) has obtained European market authorisation and is indicated "for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification". The French health authorities (Haute Autorité de Santé, HAS, and Agence Nationale de Sécurité du Médicament et des produits de santé, ANSM) have requested an evaluation of the real-life conditions of use of Selincro and its impact on morbidity.

In response, USE-PACT has been developed : a cohort of patien...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient (≥18 years) initiating Selincro
• • Patient accepting to participate
• • Patient without linguistic barrier, notably to read the information letter and to complete the self-administrated questionnaires
• • Patient not included in another study susceptible to modify patient care
• • Patient not under a guardianship
• Exclusion Criteria:
• • Minor patient (≤18 years)
• • Patient refusing to participate
• • Patient with linguistic barrier
• • Patient included in another study susceptible to modify patient care
• • Patient under a guardianship